KẾT QUẢ HÓA XẠ TRỊ TRƯỚC MỔ UNG THƯ TRỰC TRÀNG THẤP GIAI ĐOẠN II, III TẠI BỆNH VIỆN ĐÀ NẴNG

Abstract

Objective: Valuate  the  efficacy  of  neoadjuvant chemoradiation  in  the  treatment  of  stage II/III low rectal  cancer  patients and commented on some of the side effects and toxicity of this treatment. Patients and methods: 46 patients of low rectal cancer at the stages of II, III who receive radiation therapy dose of 50.4 Gy in combination with Capecitabine at the dose of 825mg/m² x 2 times/day on the days of radiation therapy, surgery is performed 5-6 weeks after the end of concurrent chemoradiation therapy in Ung Buou department, Da Nang Hospital from 6/2019 to 6/2022. Results: Overall, the response rate was 76.1%, and the complete response rate was 14.3%. The radical surgery rate was 89.7%, of which 53.8% were sphincter-conserving surgeries. Primary tumor downstaging occurred in 67.4% of the patients. Tumor volume compared with rectal circumference decreased after concurrent chemoradiation: before treatment, 37% of patients had tumors occupying the entire circumference, and this figure decreased to 8.7% after treatment, 6.5% of patients did not feel the tumor. All the hematological and non hematological toxicities were at grade 1 and tolerable. Conclusions: Neoadjuvant chemoradiation for stage II/III low rectal cancer patients could improve the response rate, radical surgery, and sphincter-conserving surgery.  This method was safe; all side effects and toxicities were low.